NCT03274687 2026-03-16
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
Clinical Trials
21 trialsNCT04624256 2026-03-13
GARUDA
Jonsson Comprehensive Cancer Center
Phase NA Active not recruiting
NCT01266642 2026-03-11
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02701153 2026-03-10
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Jonsson Comprehensive Cancer Center
Phase NA Recruiting
NCT04454528 2026-03-10
BreastVAX
Abramson Cancer Center at Penn Medicine
Phase 1/2 Active not recruiting
NCT04708067 2026-03-05
Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07447570 2026-03-03
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT00809991 2026-02-18
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04278118 2026-02-17
HiPPI
Emory University
Phase NA Recruiting
NCT07097142 2026-02-02
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT03796767 2026-01-28
SOAR
University of Utah
Phase 2 Active not recruiting
NCT05109494 2026-01-28
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
University of Wisconsin, Madison
Phase 2 Recruiting
NCT04862455 2026-01-23
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT07188532 2026-01-23
BEAR
Mayo Clinic
Phase NA Recruiting
NCT07358676 2026-01-22
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT06559540 2026-01-09
SWIFT RT
Washington University School of Medicine
Phase 2 Recruiting
NCT07327411 2026-01-08
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT02912312 2026-01-07
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03345420 2025-12-30
NOVEMBER
University of Utah
Phase 2 Completed
NCT04683653 2025-12-29
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
University of Chicago
Phase 1/2 Recruiting